Experiment Overview
| Repository ID: | FR-FCM-Z3XS | Experiment name: | Platelet activation and reactivity after BNT162b2 vaccine administration | MIFlowCyt score: | 31.50% |
| Primary researcher: | Dario Bongiovanni | PI/manager: | Dario Bongiovanni | Uploaded by: | Dario Bongiovanni |
| Experiment dates: | 2021-01-01 - 2021-03-31 | Dataset uploaded: | Apr 2021 | Last updated: | May 2021 |
| Keywords: | [platelet activation] [CyTOF] [platelets] [platelet-rich plasma] [BNT162b2 vaccine] | Manuscripts: | |||
| Organizations: |
Technical University of Munich (TUM), Department of Internal Medicine I, School of Medicine, University hospital rechts der Isar, Munich, Bavaria (Germany)
|
||||
| Purpose: | SARS-CoV-2 infection can induce a coagulopathy characterized by platelet activation and a hypercoagulable state with an increased incidence of cardiovascular events. The viral spike protein S has been reported to enhance thrombosis formation, stimulate platelets to release pro-coagulant factors and promote the formation of platelet-leukocyte aggregates even in absence of the virus. Although SARS-CoV-2 vaccines induce spike protein overexpression to trigger SARS-CoV-2-specific immune protection, thrombocyte activity has not been investigated in this context. Here, we provide the first phenotypic platelet characterization of healthy humans undergoing BNT162b2 vaccination. | ||||
| Conclusion: | In conclusion, mass cytometry of platelets after BNT162b2 vaccination did not detect any alteration of the platelet expression profile and platelet reactivity. Further studies are needed to characterize the pathophysiology of the rare thromboembolic events occuring after SARS-CoV-2 vaccination. | ||||
| Comments: | None | ||||
| Funding: | This work was supported by the German Center for Cardiovascular Research (DZHK) grant number 81X3600606 to D.B.. J.B. and M.L. are grateful for financial support from BMBF grant Sys_CARE [grant number01ZX1908A] of the Federal German Ministry of Research and Education. The work of O.L. was funded by the Bavarian State Ministry of Science and the Arts as part of the Bavarian Research Institute for Digital Transformation (bidt). | ||||
| Quality control: | Single Staining Matrix to evaluate spillover. Cisplatin Statining for cell death. Negative Control antibody. | ||||
